Tempus, a leader in precision medicine and artificial intelligence, today announced its collaboration with Precision Health Informatics, a wholly-owned subsidiary of community-based cancer care pioneer Texas Oncology, to accelerate the advancement of precision medicine in oncology. This collaboration aims to further precision medicine research through unique insights derived from Precision Health Informatics’ extensive and diverse clinical data.
Precision Health Informatics is leveraging Tempus’ AI-enabled platform and leading genomic sequencing capabilities to advance clinical research and personalized patient care. Tempus’ platform empowers physicians by providing the data they need to make critical treatment decisions. As part of the collaboration, Tempus is also supporting Precision Health Informatics in mining its database for novel insights that could inform clinical research around patient populations with unmet needs.
“Tempus aims to help uncover unique clinical insights from Precision Health Informatics’ vast database that can contribute to innovative solutions in cancer care,” said Eric Lefkofsky, Founder and CEO of Tempus. “Tempus and Precision Health Informatics are committed to providing physicians with comprehensive tools that allow physicians to tailor the treatments they are able to offer their patients, in an effort to enhance personalized medicine and dramatically improve outcomes.
“This collaboration is about developing and connecting cancer patients to precise, effective treatment. Leveraging data, Precision Health Informatics is at the forefront of precision medicine and its application to improving the standard of patient care,” Debra Patt, M.D, PhD, MBA, Executive Vice President for Public Policy and Strategic Initiatives at Texas Oncology.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
About Precision Health Informatics and Texas Oncology
Precision Health Informatics’ solutions are based on data-driven insights from a vast, diverse database. Texas Oncology is an independent private practice with more than 500 physicians and 210 locations across the state. Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, and Texas Center for Interventional Surgery. As a lead participant in US Oncology Research, Texas Oncology played a role in the development of more than 100 FDA-approved therapies, about one-third of all cancer therapies approved to date. For more information, visit www.TexasOncology.com.